Chromadex (CDXC)

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.

Company profile

Robert Fried
Fiscal year end
Former names
ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...
IRS number

CDXC stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
Low target
High target
HC Wainwright & Co.
7 Jun 22
B. Riley Securities
13 May 22

Investment data

Data from SEC filings
Securities sold
Number of investors


10 Aug 22
11 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 17.07M 17.07M 17.07M 17.07M 17.07M 17.07M
Cash burn (monthly) 1.31M 1.81M 2.13M 2.36M 1.28M 1.82M
Cash used (since last report) 1.84M 2.55M 3M 3.32M 1.8M 2.57M
Cash remaining 15.23M 14.53M 14.08M 13.76M 15.27M 14.5M
Runway (months of cash) 11.7 8.0 6.6 5.8 12.0 8.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Jun 22 Hoi Shuen Solina Holly Chau Common Stock Buy Acquire P Yes No 1.6636 60,037 99.88K 6,925,641
16 Jun 22 Wang Yu Gary Ng Stock Option Common Stock Grant Acquire A No No 1.64 20,000 32.8K 20,000
16 Jun 22 Kristin Patrick Stock Option Common Stock Grant Acquire A No No 1.64 20,000 32.8K 20,000
16 Jun 22 Ann Cohen Stock Option Common Stock Grant Acquire A No No 1.64 20,000 32.8K 20,000
16 Jun 22 Rubin Steven D Stock Option Common Stock Grant Acquire A No No 1.64 20,000 32.8K 20,000
54.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 86 86
Opened positions 13 13
Closed positions 13 19 -31.6%
Increased positions 18 29 -37.9%
Reduced positions 31 21 +47.6%
13F shares Current Prev Q Change
Total value 144.95M 218.6M -33.7%
Total shares 36.88M 36.82M +0.2%
Total puts 61K 15.8K +286.1%
Total calls 149.4K 38.3K +290.1%
Total put/call ratio 0.4 0.4 -1.0%
Largest owners Shares Value Change
Hoi Shuen Solina Holly Chau 5.96M $38.73M 0.0%
Pioneer Step 5.96M $31.58M 0.0%
Yong Rong 4.07M $10.03M -1.4%
Li Ka Shing 3.47M $12.97M 0.0%
BLK Blackrock 3.15M $7.76M -1.3%
Vanguard 2.78M $6.84M +9.5%
Tieton Capital Management 1.43M $3.52M +242.8%
ICONIQ Capital 1.3M $3.18M 0.0%
Phillip MD Frost Et Al 1.23M $11.82M 0.0%
STT State Street 932.53K $2.29M +4.1%
Largest transactions Shares Bought/sold Change
Tieton Capital Management 1.43M +1.01M +242.8%
BAC Bank Of America 792.55K -629.81K -44.3%
BCS Barclays 207.61K -568.69K -73.3%
Renaissance Technologies 420.5K +382.41K +1004.0%
First Republic Investment Management 0 -268.22K EXIT
Vanguard 2.78M +240.41K +9.5%
Millennium Management 0 -225.92K EXIT
Aqr Capital Management 413.79K +181.36K +78.0%
Marshall Wace 78.07K +78.07K NEW
GS Goldman Sachs 355.36K -75.77K -17.6%

Financial report summary

  • The COVID-19 pandemic has adversely affected, and is expected to continue to pose risks to, our business, results of operations, financial condition and cash flows, and other epidemics or outbreaks of infectious diseases may have a similar impact.
  • Global, market and economic conditions may negatively impact our business, financial condition and share price.
  • We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.
  • Our material cash requirements will depend on many factors.
  • Interruptions in our relationships or declines in our business with major customers could materially harm our business and financial results.
  • Our future success largely depends on sales of our Tru Niagen® product.
  • Changes in our business strategy, including entering the consumer product market, or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses.
  • The success of our consumer product and ingredient business is linked to the size and growth rate of the vitamin, mineral and dietary supplement market and an adverse change in the size or growth rate of that market could have a material adverse effect on us.
  • The future growth and profitability of our consumer product business will depend in large part upon the effectiveness and efficiency of our marketing efforts and our ability to select effective markets and media in which to market and advertise.
  • We face significant competition, including changes in pricing.
  • Many of our competitors are larger and have greater financial and other resources than we do.
  • Litigation may harm our business.
  • Our sales and results of operations for our analytical reference standards and services segment depend on our customers’ research and development efforts and their ability to obtain funding for these efforts.
  • Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.
  • We may need to increase the size of our organization, and we can provide no assurance that we will successfully expand operations or manage growth effectively.
  • The insurance industry has become more selective in offering some types of coverage and we may not be able to obtain insurance coverage in the future.
  • We may bear financial risk if we underprice our contracts or overrun cost estimates.
  • If we experience a significant disruption in our information technology systems or if we fail to implement new systems and software successfully, our business could be adversely affected.
  • If we are unable to maintain sales, marketing and distribution capabilities or maintain arrangements with third parties to sell, market and distribute our products, our business may be harmed.
  • Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
  • We are subject to financial and operating covenants in our business financing agreement with Western Alliance Bank, as amended (Credit Agreement) and any failure to comply with such covenants, or obtain waivers in the event of non-compliance, could limit our borrowing availability under the Credit Agreement, resulting in our being unable to borrow under the Credit Agreement and materially adversely impact our liquidity. In addition, our operations may not provide sufficient cash to meet the repayment obligations of debt incurred under the Credit Agreement.
  • Our business could be negatively impacted by cyber security threats, including without limitation a material interruption to our operations including our clinical trials, harm to our reputation, significant fines, penalties and liabilities, breach or triggering of data protection laws, privacy policies and data protection obligations, or a loss of customers or sales.
  • Unfavorable publicity or consumer perception of our products and any similar products distributed by other companies could have a material adverse effect on our business.
  • We utilize ingredients and components for our products from foreign suppliers, and may be negatively affected by the risks associated with international trade and importation issues.
  • We may never develop any additional products to commercialize.
  • We may not be able to partner with others for technological capabilities and new products and services.
  • If we fail to maintain adequate quality standards for our products and services, our business may be adversely affected and our reputation harmed.
  • If we experience product recalls, we may incur significant and unexpected costs, and our business reputation could be adversely affected.
  • Demand for our products and services are subject to the commercial success of our customers’ products, which may vary for reasons outside our control.
  • We rely on single or a limited number of third-party suppliers for the raw materials required to produce our products.
  • Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which would have a material and adverse effect on us.
  • Our patents and licenses may be subject to challenge on validity grounds, and our patent applications may be rejected.
  • We may become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives and subject us to substantial monetary damages.
  • The prosecution and enforcement of patents licensed to us by third parties are not within our control. Without these technologies, our products may not be successful and our business would be harmed if the patents were infringed on or misappropriated without action by such third parties.
  • We are currently engaged in substantial and complex litigation with Elysium Health, Inc. and Elysium Health LLC (collectively, "Elysium"), the outcome of which could materially harm our business and financial results.
  • We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets of others.
  • We are subject to regulation by various federal, state and foreign agencies that require us to comply with a wide variety of regulations, including those regarding the manufacture of products, advertising and product label claims, the distribution of our products and environmental matters. Failure to comply with these regulations could subject us to fines, penalties and additional costs.
  • Government regulations of our customer’s business are extensive and are constantly changing. Changes in these regulations can significantly affect customer demand for our products and services.
  • Changes in government regulation or in practices relating to the pharmaceutical, dietary supplement, food and cosmetic industry could decrease the need for the services we provide.
  • If we should in the future become required to obtain regulatory approval to market and sell our goods we will not be able to generate any revenues until such approval is received.
  • Compliance with stringent and changing global privacy and data security laws and regulations could result in additional costs and liabilities to us or inhibit our ability to collect and, if applicable, process data globally, and the failure or perceived failure to comply with such laws and regulations could have a material adverse effect on our business, financial condition or results of operations.
  • The market price of our common stock may be volatile and adversely affected by several factors.
  • We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
  • Our ability to use our net operating loss (NOL) carryforwards and certain other tax attributes may be limited.
  • We have a significant number of outstanding options and unvested restricted stock units. Future sales of these shares could adversely affect the market price of our common stock.
  • Our bylaws, as amended (Bylaws) provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • We may become involved in securities class action litigation that could divert management’s attention and harm our business.
  • Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
  • Our shares of common stock may be thinly traded, so you may be unable to sell at or near ask prices or at all.
  • Stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.
Management Discussion
  • (1) Includes approximately 0.2 million nonvested shares of restricted stock for the year ended December 31, 2021 and December 31, 2020 which are participating securities that feature voting and dividend rights.
  • (2) Excluded from the computation of loss per share as their impact is antidilutive.
  • Net Sales. Net sales consist of gross sales less discounts and returns. Our total net sales grew from $21.2 million in 2017 to $67.4 million in 2021, representing a 26% compound annual growth rate.

Content analysis

H.S. sophomore Good
New words: advocacy, advocate, affiliated, anniversary, begun, Blue, burn, campaign, certainty, Chau, Chiba, China, Chinese, climate, Connecticut, considerable, coupled, Crystal, deadline, designee, deviate, domestic, drove, equitable, ERTC, ESG, focused, formation, fulfillment, Hat, headcount, hold, holding, House, Idea, indirectly, influential, JV, Ka, Lake, Li, Macau, Mainland, mission, month, nominal, ostensibly, overseeing, path, payroll, policy, PRC, preferential, properly, representing, repurchase, Shing, society, Solina, spanning, sporadic, stakeholder, strength, Sun, swift, Taikuk, Taiwan, Territory, Treasury, undermine, unpatentable, unrestricted, venture
Removed: accrued, collective, Farr, Frank, Jaksch, Jr, Kevin, payable, posted, reclassified, relate, testing